ReviewGalen medical journal2024
Advances in Regenerative Medicine for the Treatment of Osteonecrosis of the Jaw.
Review in Galen medical journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteonecrosis of the jaw (ONJ) is a debilitating condition characterized by progressive bone tissue necrosis, commonly linked to bisphosphonates, radiation therapy, or trauma. Traditional treatments, such as surgical debridement and conservative management, often fail to fully restore bone function, driving the need for alternative therapeutic strategies. Regenerative medicine, particularly cellular therapies and biomaterials, has emerged as a promising field in ONJ treatment. This review explores recent advancements in regenerative approaches for ONJ, with a focus on Mesenchymal stem cells (MSCs) and bioengineered scaffolds. MSCs, with their dual ability to differentiate into osteoblasts and modulate immune responses, play a crucial role in bone regeneration by both forming new bone tissue and reducing inflammation. Bioengineered scaffolds, such as hydrogels, bioactive ceramics, and nanomaterials, provide essential structural support and create a conducive environment for cellular growth and tissue repair. The combination of MSCs with these biomaterials has demonstrated a synergistic effect, significantly enhancing bone healing and regeneration. Additionally, emerging techniques such as platelet-rich plasma (PRP), platelet-rich fibrin (PRF), and bone morphogenetic proteins (BMPs) offer new avenues for improving clinical outcomes in ONJ patients. However, several challenges remain, including regulatory barriers, the need for standardized cell isolation and delivery protocols, and scalability issues for clinical application. This review further examines emerging technologies, such as 3D bioprinting and personalized medicine, which offer the potential to tailor regenerative treatments to individual patients, thereby improving both the efficacy and longevity of therapies. In conclusion, while significant progress has been made in the application of regenerative medicine for ONJ, continued research is essential to address current limitations, optimize treatment protocols, and ensure broader clinical adoption. Advances in cellular therapies and biomaterials hold transformative potential for improving therapeutic outcomes in patients with ONJ.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.